fbpx

TERESA MACARULLA

TERESA MACARULLA

 


Posició actual

  • Teresa Macarulla és metge adjunt del Servei de Tumors Gastrointestinals del Servei d’Oncologia Mèdica de l’Hospital Universitari Vall d’Hebron. Actualment també és Investigadora Principal del Grup de Tumors Gastrointestinals i Endocrins del VHIO, encapçalat per Josep Tabernero, director de VHIO.

Titulacions acadèmiques

  • Teresa Macarulla es va llicenciar en Medicina per la Universitat Autònoma de Barcelona, ​​Espanya, i va realitzar la seva residència al Departament d’Oncologia Mèdica de l’Hospital Universitari Sant Pau, Universitat Autònoma de Barcelona, ​​i va obtenir el seu Doctorat en Medicina i Cirurgia a la Universitat Autònoma de Barcelona amb “Cum Laude” el 2015.

Àrees de recerca

És coinvestigadora de diversos estudis encaminats a desenvolupar molècules noves contra el càncer, especialment en el camp de la inhibició de l’EGFR (receptor d’el factor de creixement epidèrmic), les mutacions o hiperactivitat s’han associat a el desenvolupament de el càncer. Està especialitzada en noves teràpies dirigides contra tumors GI, especialment càncers de còlon, hepatocarcinoma, pàncrees i vies biliars. A més, assumeix un paper clau dins el Servei d’Oncologia Mèdica de l’Hospital Universitari Vall d’Hebron (HUVH).

  • Investigació clínica: com metgessa adjunta de el Departament d’Oncologia Mèdica de HUVH i com a investigadora principal d’el Grup de Tumors gastrointestinals i Endocrins d’VHIO, una de les seves principals tasques és la investigació i els estudis clínics. En els tumors gastrointestinals, els pacients s’inclouen en assaigs clínics (fase I, II o III) específicament dedicats a millorar en última instància els resultats de les persones amb càncers de còlon, gàstric, hepatocarcinoma, pàncrees, biliars i esofàgics malignes. Ha participat i contribuït en el disseny d’estudis clínics ja sigui com Investigadora Principal o com a part d’assajos desenvolupats en el context de grups cooperatius nacionals i internacionals, així com els recolzats per empreses farmacèutiques.
  • Recerca preclínica: està compromesa amb el desenvolupament de noves teràpies i estudis de fase I en tumors sòlids. Els seus interessos particulars se centren en el desenvolupament de teràpies de diana moleculars amb especial èmfasi en la definició de la dosi ideal biològica a través de l’anàlisi de farmacocinètica / farmacodinàmica. Simultàniament, també ha contribuït a la caracterització de biomarcadors moleculars d’eficàcia clínica en assajos de fase I.
  • Marcadors moleculars en tumors gastrointestinals: Teresa Macarulla també es dedica a promoure coneixements sobre factors predictius de resposta i eficàcia en diversos tumors gastrointestinals.

Premis i beques

  • Nanomedicine Upscaling for Early Clinical Phases of Multimodal Cancer Therapy (NoCanTher). H2020 Framework Programme. Principal Investigator.
  • FP7-HEALTH-2013-602901 (MERCURIC): Phase I study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor PF-02341066 in KRASMT and KRASWT (with aberrant c-MET) Colorectal Cancer Patients. Co-Investigator. 2013-2020.
  • RD12/0036/0012. CARLOS III HEALTH INSTITUTE. Cancer Cooperative Research Thematic Network (RTICC). Co-Investigator. 2013-2016.
  • Collaborative research of Anti-Epiregulin (EREG) Antibody project for promotion of personalized healthcare (PHD). CHUGAI PHARMACEUTICAL CO. LTD. Co-Investigator. 2013-2014.
  • PI11/00917. CARLOS III HEALTH INSTITUTE: Identification of predictive biomarkers of response and resistance to biological treatment and identification of subtypes in metastatic colorectal cancer (mCRC). Co-Investigator. 2015-2017.
  • European Commission Horizon 2020. ref.635342. Molecularly guided trials with specific treatment strategies in patients with advanced newly molecular defined subtypes of colorectal cancer (MoTriColor). Co-Investigator. 2015-2018.
  • Development of a systems biology method to predict efficacy of cancer drugs to optimize individualized therapeutics decision and improve clinical outcome for cancer patients (WINTHER). Seventh Framework Program. Co-Investigator

Publicacions científiques més rellevants

  • Kopetz S, Grothey A, Yaeger R, Van Cutsem E, Desai J, Yoshino T, Wasan H, Ciardiello F, Loupakis F, Hong YS, Steeghs N, Guren TK, Arkenau HT, Garcia-Alfonso P, Pfeiffer P, Orlov S, Lonardi S, Elez E, Kim TW, Schellens JHM, Guo C, Krishnan A, Dekervel J, Morris V, Calvo Ferrandiz A, Tarpgaard LS, Braun M, Gollerkeri A, Keir C, Maharry K, Pickard M, Christy-Bittel J, Anderson L, Sandor V, Tabernero J. Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer. N Engl J Med. 2019 Oct 24;381(17):1632-1643.
  • Golan T, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, Park JO, Hochhauser D, Arnold D, Oh DY, Reinacher-Schick A, Tortora G, Algül H, O’Reilly EM, McGuinness D, Cui KY, Schlienger K, Locker GY, Kindler HL. Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. N Engl J Med. 2019 Jul 25;381(4):317-327.
  • Macarulla T, Pazo-Cid R, Guillén-Ponce C, López R, Vera R, Reboredo M, Muñoz Martin A, Rivera F, Díaz Beveridge R, La Casta A, Martín Valadés J, Martínez-Galán J, Ales I, Sastre J, Perea S, Hidalgo M. Phase I/II Trial to Evaluate the Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel in Combination With Gemcitabine in Patients With Pancreatic Cancer and an ECOG Performance Status of 2. J Clin Oncol. 2019 Jan 20;37(3):230-238.
  • Yoshino T, Portnoy DC, Obermannová R, Bodoky G, Prausová J, Garcia-Carbonero R, Ciuleanu T, García-Alfonso P, Cohn AL, Van Cutsem E, Yamazaki K, Lonardi S, Muro K, Kim TW, Yamaguchi K, Grothey A, O’Connor J, Taieb J, Wijayawardana SR, Hozak RR, Nasroulah F, Tabernero J. Biomarker analysis beyond angiogenesis: RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE-a global phase III study. Ann Oncol. 2019 Jan 1;30(1):124-131.
  • De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, Kalogeras KT, Kotoula V, Papamichael D, Laurent-Puig P, Penault-Llorca F, Rougier P, Vincenzi B, Santini D, Tonini G, Cappuzzo F, Frattini M, Molinari F, Saletti P, De Dosso S, Martini M, Bardelli A, Siena S, Sartore-Bianchi A, Tabernero J, Macarulla T, Di Fiore F, Gangloff AO, Ciardiello F, Pfeiffer P, Qvortrup C, Hansen TP, Van Cutsem E, Piessevaux H, Lambrechts D, Delorenzi M, Tejpar S. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010 Aug; 11(8):753-62.
  • Wolpin BM, O’Reilly EM, Ko YJ, Blaszkowsky LS, Rarick M, Rocha-Lima CM, Ritch P, Chan E, Spratlin J, Macarulla T, McWhirter E, Pezet D, Lichinitser M, Roman L, Hartford A, Morrison K, Jackson L, Vincent M, Reyno L, Hidalgo M. Global, multicenter, randomized, phase II trial of gemcitabine and gemcitabine plus AGS-1C4D4 in patients with previously untreated, metastatic pancreatic cancer. Ann Oncol. 2013 Jul; 24(7):1792-801
  • Heinemann V, Reni M, Ychou M, Richel DJ, Macarulla T, Ducreux M. Tumour-stroma interactions in pancreatic ductal adenocarcinoma: rationale and current evidence for new therapeutic strategies. Cancer Treat Rev. 2014 Feb; 40(1):118-28.
  • Roepman P, Schlicker A, Tabernero J, Majewski I, Tian S, Moreno V, Snel MH, Chresta CM, Rosenberg R, Nitsche U, Macarulla T, Capella G, Salazar R, Orphanides G, Wessels LF, Bernards R, Simon IM. Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition. Int J Cancer. 2014 Feb 1; 134(3):552-62.
  • Elez ME, Tabernero J, Geary D, Macarulla T, Kang SP, Kahatt C, Pita AS, Teruel CF, Siguero M, Cullell-Young M, Szyldergemajn S, Ratain MJ. First-in-human phase I study of Lurbinectedin (PM01183) in patients with advanced solid tumors. Clin Cancer Res. 2014 Apr 15; 20(8):2205-14.
  • Geva R, Vecchione L, Kalogeras KT, Vittrup Jensen B, Lenz HJ, Yoshino T, Paez D, Montagut C, Souglakos J, Cappuzzo F, Cervantes A, Frattini M, Fountzilas G, Johansen JS, Høgdall EV, Zhang W, Yang D, Yamazaki K, Nishina T, Papamichael D, Vincenzi B, Macarulla T, Loupakis F, De Schutter J, Spindler KL, Pfeiffer P, Ciardiello F, Piessevaux H, Tejpar S. FCGR polymorphisms and cetuximab efficacy in chemorefractory metastatic colorectal cancer: an international consortium study. Gut. 2014 Jul 10. pii: gutjnl-2014-307234.
  • Macarulla T, Sauri T, Tabernero J. Evaluation of aflibercept in the treatment of metastatic colorectal cancer. Expert Opin Biol Ther. 2014 Oct; 14(10):1493-505.
  • Bonnetain F, Bonsing B, Conroy T, Dousseau A, Glimelius B, Haustermans K, Lacaine F, Van Laethem JL, Aparicio T, Aust D, Bassi C, Berger V, Chamorey E, Chibaudel B, Dahan L, De Gramont A, Delpero JR, Dervenis C, Ducreux M, Gal J, Gerber E, Ghaneh P, Hammel P, Hendlisz A, Jooste V, Labianca R, Latouche A, Lutz M, Macarulla T, Malka D, Mauer M, Mitry E, Neoptolemos J, Pessaux P, Sauvanet A, Tabernero J, Taieb J, van Tienhoven G, Gourgou-Bourgade S, Bellera C, Mathoulin-Pélissier S, Collette L. Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event End-points in Cancer trials. Eur J Cancer. 2014 Nov; 50(17):2983-93
  • Katsila T, Juliachs M, Gregori J, Macarulla T, Villarreal L, Bardelli A, Torrance C, Elez E, Tabernero J, Villanueva J. Circulating pEGFR is a candidate response biomarker of cetuximab therapy in colorectal cancer. Clin. Cancer Res. 2014 Dec 15; 20(24):6346-56.
  • Ruff P, Ferry DR, Lakomỳ R, Prausová J, Van Hazel GA, Hoff PM, Cunningham D, Arnold D, Schmoll HJ, Moiseyenko VM, McKendrick JJ, Ten Tije AJ, Vishwanath RL, Bhargava P, Chevalier S, Macarulla T, Van Cutsem E. Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy. Eur J Cancer. 2015 Jan; 51(1):18-26
  • Sanz-Garcia E, Saurí T, Tabernero J, Macarulla T.Pharmacokinetic and pharmacodynamic evaluation of aflibercept for the treatment of colorectal cancer. Expert Opin Drug Metab Toxicol. 2015 Jun; 11(6):995-1004. Doi: 10.1517/17425255.2015.1041920. Review.
  • Macarulla T, Cervantes A, Tabernero J, Roselló S, Van Cutsem E, Tejpar S, Prenen H, Martinelli E, Troiani T, Laffranchi B, Jego V, von Richter O, Ciardiello F.Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer.Br J Cancer. 2015 Jun 9; 112(12):1874-81. Doi: 10.1038/bjc.2015.144. Epub 2015 May
  • Carrato A, García P, López R, Macarulla T, Rivera F, Sastre J, Gostkorzewicz J, Benedit P, Pérez-Alcántara F.Cost-utility analysis of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in combination with gemcitabine in metastatic pancreatic cancer in Spain: results of the PANCOSTABRAX study. Expert Rev Pharmacoecon Outcomes Res. 2015; 15(4):579-89. Doi: 10.1586/14737167.2015.1047349. Epub 2015 May 19.
  • Benavides M, Antón A, Gallego J, Gómez MA, Jiménez-Gordo A, La Casta A, Laquente B, Macarulla T, Rodríguez-Mowbray JR, Maurel J.Biliary tract cancers: SEOM clinical guidelines. ClinTransl Oncol. 2015 Dec; 17(12):982-7. Doi: 10.1007/s12904 – 015-1436-2. Epub 2015 Nov 25.
  • Van Cutsem E, Joulain F, Hoff PM, Mitchell E, Ruff P, Lakomý R, Prausová J, Moiseyenko VM, van Hazel G, Cunningham D, Arnold D, Schmoll HJ, Ten Tije AJ, McKendrick J, Kröning H, Humblet Y, Grávalos C, Le-Guennec S, Andria M, Dochy E, Vishwanath RL, Macarulla T, Tabernero J. Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing Adjuvant Oxaliplatin-Based Therapy. Target Oncol. 2015 Dec 26. [Epub ahead of print).
  • Goldstein D, Von Hoff DD, Moore M, Greeno E, Tortora G, Ramanathan RK, Macarulla T, Liu H, Pilot R, Ferrara S, Lu B. Development of peripheral neuropathy and its association with survival during treatment with nab-paclitaxel plus gemcitabine for patients with metastatic adenocarcinoma of the pancreas: A subset analysis from a randomized phase III trial (MPACT). Eur J Cancer. 2016 Jan; 52:85-91. Doi: 10.1016/j.ejca.2015.10.017. Epub 2015 Dec 1.
  • Wang-Gillam A, Li CP, Bodoky G, Dean A, Shan YS, Jameson G, Macarulla T, Lee KH, Cunningham D, Blanc JF, Hubner RA, Chiu CF, Schwartsmann G, Siveke JT, Braiteh F, Moyo V, Belanger B, Dhindsa N, Bayever E, Von Hoff DD, Chen LT; NAPOLI-1 Study Group. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet. 2016 Feb 6; 387(10018):545-57. Doi: 10.1016/S0140-6736(15)00986-1. Epub 2015 Nov 29. Erratum in:Lancet. 2016 Feb 6; 387(10018):536
  • Verdaguer H, Tabernero J, Macarulla T. Ramucirumab in metastatic colorectal cancer: evidence to date and place in therapy. Ther Adv Med Oncol 2016 May 8(3):230–42.
  • Scheithauer W, Ramanathan RK, Moore M, Macarulla T, Goldstein D, Hammel P, et al. Dose modification and efficacy of nab-paclitaxel plus gemcitabine vs. gemcitabine for patients with metastatic pancreatic cancer: phase III MPACT trial. J Gastrointest Oncol. 2016 Jun; 7(3):469-78. Doi: 10.21037/jgo.2016.01.03.
  • M. Hidalgo , R. Álvarez , J. Gallego , C. Guillén-Ponce , B. Laquente , T. Macarulla  A. Muñoz , M. Salgado , R. Vera , J . Adeva ,  I. Alés ,  S. Arévalo , J. Blázquez , A. Calsina ,  A. Carmona ,  E. de Madaria , R. Díaz ,  L. Díez  T. Fernández ,  B. G. de Paredes , M. E. Gallardo , I. González , O. Hernando ,  P. Jiménez , A. López , C. López ,  F. López-Ríos , E. Martín , J. Martínez , A. Martínez,  J. Montans , R. Pazo , J. C. Plaza , I. Peiró ,  J. J. Reina , A. Sanjuanbenito , R. Yaya , Alfredo Carrato. Consensus guidelines for diagnosis, treatment and follow-up of patients with pancreatic cancer in Spain. Clin. Transl. Oncol. 2017 19-6, pp.667-681.
  • Grasselli J , Elez E , Caratù G  , Matito J  , Santos C  , Macarulla T  , Vidal J , Garcia M  , Viéitez JM  , Paéz D  , Falcó E  , lopez lopez C  ,Aranda E  , Jones F  , Sikri V  , Nuciforo P  , Fasani R  , Tabernero J  , Montagut C  , Azuara D  , Dienstmann R  , Salazar R  , Vivancos A. Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer. Ann Oncol.2017 Jun 1; 28 (6): 1294-1301. doi: 10.1093 / annonc / mdx112.
  • Saura C  , Roda D  , Roselló S  , Oliveira M  , Macarulla T  , Pérez-Fidalgo JA , Morales-Barrera R  , Sanchis-García JM  , Musib L  , Budha N  , Zhu J  , Nannini M  , Chan WY  , Sanabria Bohórquez SM  , Meng RD , Lin K , Yan Y , Patel P  , Baselga J  , Tabernero J  , Cervantes A . A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors. Cancer Discov.7-1, pp.102-113.